R
Ron Ram
Researcher at Tel Aviv University
Publications - 60
Citations - 1142
Ron Ram is an academic researcher from Tel Aviv University. The author has contributed to research in topics: Transplantation & Hematopoietic stem cell transplantation. The author has an hindex of 17, co-authored 60 publications receiving 804 citations. Previous affiliations of Ron Ram include Rabin Medical Center & Tel Aviv Sourasky Medical Center.
Papers
More filters
Journal ArticleDOI
Randomized Phase III Study of Lenalidomide Versus Placebo in RBC Transfusion-Dependent Patients With Lower-Risk Non-del(5q) Myelodysplastic Syndromes and Ineligible for or Refractory to Erythropoiesis-Stimulating Agents
Valeria Santini,Antonio Almeida,Aristoteles Giagounidis,Stefanie Gröpper,Anna Jonasova,Norbert Vey,Ghulam J. Mufti,Rena Buckstein,Moshe Mittelman,Uwe Platzbecker,Ofer Shpilberg,Ron Ram,Consuelo del Cañizo,Norbert Gattermann,Keiya Ozawa,Alberto Risueño,Kyle J. MacBeth,Jianhua Zhong,Francis Séguy,Albert Hoenekopp,C.L. Beach,Pierre Fenaux +21 more
TL;DR: In this article, the authors evaluated the efficacy and safety of lenalidomide in RBC transfusion-dependent patients with International Prognostic Scoring System lower-risk non-del(5q) myelodysplastic syndromes ineligible for or refractory to erythropoiesis-stimulating agents.
Journal ArticleDOI
Safety and Immunogenicity of the BNT162b2 mRNA COVID-19 Vaccine in Patients after Allogeneic HCT or CD19-based CART therapy-A Single-Center Prospective Cohort Study.
Ron Ram,David Hagin,Nino Kikozashvilli,Tal Freund,Tal Freund,Odelia Amit,Yael Bar-On,Ofrat Beyar-Katz,Gabi Shefer,Miguel Morales Moshiashvili,Miguel Morales Moshiashvili,Chen Karni,Ronit Gold,Sigi Kay,Chen Glait-Santar,Rinat Eshel,Chava Perry,Irit Avivi,Arie Apel,Noam Benyamini,David Shasha,Ronen Ben-Ami,Ronen Ben-Ami +22 more
TL;DR: The BNT162b2 mRNA COVID-19 vaccine has impressive immunogenicity in patients after allogeneic hematopoietic cell transplantation (HCT) or after CD19-based chimeric antigen receptor T cell (CART) therapy as mentioned in this paper.
Journal ArticleDOI
Management of adult patients with acute lymphoblastic leukemia in first complete remission: systematic review and meta-analysis.
Ron Ram,Ron Ram,Anat Gafter-Gvili,Anat Gafter-Gvili,Liat Vidal,Liat Vidal,Mical Paul,Mical Paul,Isaac Ben-Bassat,Ofer Shpilberg,Ofer Shpilberg,Pia Raanani,Pia Raanani +12 more
TL;DR: This study compared the various potential therapeutic options for patients who achieved first complete remission with the optimal postremission therapy in adults with acute lymphoblastic leukemia.
Journal ArticleDOI
Cannabidiol for the Prevention of Graft-versus-Host-Disease after Allogeneic Hematopoietic Cell Transplantation: Results of a Phase II Study.
Moshe Yeshurun,Moshe Yeshurun,Ofer Shpilberg,Ofer Shpilberg,Corina Herscovici,Corina Herscovici,Liat Shargian,Liat Shargian,Juliet Dreyer,Anat Peck,Moshe Israeli,Maly Levy-Assaraf,Tsipora Gruenewald,Raphael Mechoulam,Pia Raanani,Pia Raanani,Ron Ram,Ron Ram +17 more
TL;DR: The combination of CBD with standard GV HD prophylaxis is a safe and promising strategy to reduce the incidence of acute GVHD.
Journal ArticleDOI
Busulfan fludarabine vs busulfan cyclophosphamide as a preparative regimen before allogeneic hematopoietic cell transplantation: systematic review and meta-analysis
S Ben-Barouch,S Ben-Barouch,Omri Cohen,Omri Cohen,Liat Vidal,Liat Vidal,Irit Avivi,Irit Avivi,Ron Ram,Ron Ram +9 more
TL;DR: Both regimens have similar efficacy profiles, whereas toxicity is lower with the Bu–Flu regimen, a systematic review and meta-analysis of all comparative trials concluded.